Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
369.53
+1.93 (0.53%)
At close: Mar 6, 2026, 4:00 PM EST
368.51
-1.02 (-0.28%)
After-hours: Mar 6, 2026, 7:21 PM EST

Amgen Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
7,7114,0906,7176,5525,893
Depreciation & Amortization
5,1675,5924,0713,4173,398
Stock-Based Compensation
494530431401341
Other Adjustments
-1,436-1,087-2,26484823
Change in Receivables
-2,676441-1,015-746-429
Changes in Inventories
8862,532491-742-165
Changes in Accounts Payable
428312-402154-69
Changes in Accrued Expenses
4999295397-
Changes in Income Taxes Payable
-2,068-1,011-1,031-647-854
Changes in Other Operating Activities
953-15201,151323
Operating Cash Flow
9,95811,4908,4719,7219,261
Operating Cash Flow Growth
-13.33%35.64%-12.86%4.97%-11.77%
Capital Expenditures
-1,858-1,096-1,112-936-880
Purchases of Investments
----2,587-8,900
Proceeds from Sale of Investments
--1,6731,21813,234
Payments for Business Acquisitions
-53--26,989-3,839-2,529
Other Investing Activities
-3250224100-192
Investing Cash Flow
-1,943-1,046-26,204-6,044733
Long-Term Debt Issued
--27,7776,9194,945
Long-Term Debt Repaid
-5,683-4,259-2,101-297-4,150
Net Long-Term Debt Issued (Repaid)
-5,683-4,25925,6766,622795
Repurchase of Common Stock
--200--6,360-4,975
Net Common Stock Issued (Repurchased)
--200--6,360-4,975
Common Dividends Paid
-5,124-4,832-4,556-4,196-4,013
Other Financing Activities
-52-124-72-103-78
Financing Cash Flow
-10,859-9,41521,048-4,037-8,271
Net Cash Flow
-2,8441,0293,315-3601,723
Free Cash Flow
8,10010,3947,3598,7858,381
Free Cash Flow Growth
-22.07%41.24%-16.23%4.82%-15.25%
FCF Margin
22.04%31.10%26.11%33.37%32.26%
Free Cash Flow Per Share
14.9419.2113.6816.2414.63
Levered Free Cash Flow
6,0356,25135,88315,6688,441
Unlevered Free Cash Flow
11,80712,86110,24311,0268,471
Updated Feb 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q